News about IART

Integra reported Q3 2026 revenue of $411.2 million, up 2.5% organically despite a $7 million hit from flood damage at its Cincinnati facility, with adjusted EPS of $0.59 versus $0.54 a year earlier. Specialty Surgery grew 4.2% organically to $304.1 million, led by neurosurgery (up 6.5%) and international markets (up 7.8%), while Tissue Reconstruction fell 2.2% organically to $107.1 million amid competition in the urinary bladder matrix (UBM) portfolio. Management expects a $15 million to $20 million revenue reduction in Q4 as the Cincinnati site recovers, and updated full-year 2026 revenue guidance to $1.634 billion to $1.654 billion, lowering its midpoint, with adjusted EPS guidance of $2.30 to $2.40. The company completed a $2.1 billion debt refinancing on Oct. 19, 2026, with net debt of $1.5 billion and a 3.8x leverage ratio, but expects about $8 million in extra interest expense in Q4 and $24 million more in 2027.